Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions
- PMID: 32101575
- PMCID: PMC7043761
- DOI: 10.1371/journal.pone.0229534
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions
Abstract
Temozolomide (TMZ) is a drug of choice in glioblastoma treatment. Its therapeutic applications expand also beyond high grade gliomas. However, a significant number of recurrences and resistance to the drug is observed. The key factor in each chemotherapy is to achieve the therapeutic doses of a drug at the pathologic site. Nonetheless, the rate of temozolomide penetration from blood to cerebrospinal fluid is only 20-30%, and even smaller into brain intestinum. That makes a challenge for the therapeutic regimens to obtain effective drug concentrations with minimal toxicity and minor side effects. The aim of our research was to explore a novel epigenetic mechanism of temozolomide action in therapeutic conditions. We analyzed the epigenetic effects of TMZ influence on different glioblastoma cell lines in therapeutically achieved TMZ concentrations through total changes of the level of 5-methylcytosine in DNA, the main epigenetic marker. That was done with classical approach of radioactive nucleotide post-labelling and separation on thin-layer chromatography. In the range of therapeutically achieved temozolomide concentrations we observed total DNA hypomethylation. The significant hypermethylating effect was visible after reaching TMZ concentrations of 10-50 μM (depending on the cell line). Longer exposure time promoted DNA hypomethylation. The demethylated state of the glioblastoma cell lines was overcome by repeated TMZ applications, where dose-dependent increase in DNA 5-methylcytosine contents was observed. Those effects were not seen in non-cancerous cell line. The increase of DNA methylation resulting in global gene silencing and consecutive down regulation of gene expression after TMZ treatment may explain better glioblastoma patients' survival.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures











Similar articles
-
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.Clin Epigenetics. 2019 May 14;11(1):76. doi: 10.1186/s13148-019-0670-9. Clin Epigenetics. 2019. PMID: 31088577 Free PMC article.
-
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.PLoS One. 2015 Aug 26;10(8):e0136669. doi: 10.1371/journal.pone.0136669. eCollection 2015. PLoS One. 2015. PMID: 26309255 Free PMC article.
-
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.Int J Oncol. 2009 Jul;35(1):139-48. doi: 10.3892/ijo_00000322. Int J Oncol. 2009. PMID: 19513561
-
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):296-302. doi: 10.2176/nmc.ra.2018-0040. Epub 2018 Jun 13. Neurol Med Chir (Tokyo). 2018. PMID: 29899179 Free PMC article. Review.
-
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Int J Oncol. 2015 Aug;47(2):417-28. doi: 10.3892/ijo.2015.3026. Epub 2015 May 29. Int J Oncol. 2015. PMID: 26035292 Free PMC article. Review.
Cited by
-
Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate.Cell Commun Signal. 2024 Jan 11;22(1):30. doi: 10.1186/s12964-023-01277-z. Cell Commun Signal. 2024. PMID: 38212807 Free PMC article.
-
Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases.Front Pharmacol. 2022 Apr 26;13:815646. doi: 10.3389/fphar.2022.815646. eCollection 2022. Front Pharmacol. 2022. PMID: 35559231 Free PMC article.
-
Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines.Front Oncol. 2022 Nov 16;12:1033035. doi: 10.3389/fonc.2022.1033035. eCollection 2022. Front Oncol. 2022. PMID: 36465345 Free PMC article.
-
The role of RNA modification in the generation of acquired drug resistance in glioma.Front Genet. 2022 Nov 11;13:1032286. doi: 10.3389/fgene.2022.1032286. eCollection 2022. Front Genet. 2022. PMID: 36437944 Free PMC article. Review.
-
Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.Int J Mol Sci. 2020 Aug 6;21(16):5631. doi: 10.3390/ijms21165631. Int J Mol Sci. 2020. PMID: 32781585 Free PMC article. Review.
References
-
- Li RH, Hou XY, Yang CS, Liu WL, Tang JQ, Liu YQ, et al. Temozolomide for Treating Malignant Melanoma. J Coll Physicians Surg Pak. 2015;25:680–688 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources